Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Michael Matyas

Diagnostic Radiology Albuquerque, NM Medical Doctor

NPI 1538162912 CMS profile 1204106

8020 Constitution Pl Ne, Suite 202, Albuquerque, NM 87110

Open in the dashboard

General payments

$203

3 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Michael Matyas of Albuquerque, NM is reported in the CMS Open Payments database as having received $203 across 3 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $203 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Matyas
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Michael Matyas were reported at $0. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Michael Matyas Diagnostic Radiology median Middle half National median
2019 $203 $108 $29–$318 $163
2020 $0 $65 $21–$252 $114
2021 $0 $92 $24–$292 $132
2022 $0 $104 $29–$294 $149
2023 $0 $110 $29–$337 $160
2024 $0 $113 $30–$356 $164
2025 $0 $112 $32–$349 $169

Breakdown

Who paid General payments · program year 2019
  1. Genentech USA, Inc. $100 1 payment
  2. Pfizer Inc. $79 1 payment
  3. Astellas Pharma US Inc $24 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $203 3 payments
Products named General payments · program year 2019
  1. VYNDAQEL $79 1 payment
  2. Lexiscan $24 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 120 billing codes

Paid by Medicare

$88,083

Of which drugs: $518

Medicare patients

1,670

Average age 73

Services billed

7,684

1,108 women, 562 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 44%
Ischemic heart disease 44%
Chronic kidney disease 41%
Heart failure 36%
Depression 33%
COPD 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadoterate meglumine, 0.1 ml A9575 Office 22 3,790 $365
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 16 1,490 $153

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record